MRK
Price
$89.76
Change
+$0.53 (+0.59%)
Updated
Mar 31 closing price
Capitalization
331.75B
23 days until earnings call
NVS
Price
$111.48
Change
-$1.09 (-0.97%)
Updated
Mar 31 closing price
Capitalization
197.93B
28 days until earnings call
Ad is loading...

MRK vs NVS

Header iconMRK vs NVS Comparison
Open Charts MRK vs NVSBanner chart's image
Merck & Co
Price$89.76
Change+$0.53 (+0.59%)
Volume$15M
Capitalization331.75B
Novartis AG
Price$111.48
Change-$1.09 (-0.97%)
Volume$2.95M
Capitalization197.93B
MRK vs NVS Comparison Chart
Loading...
MRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MRK vs. NVS commentary
Apr 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a Hold and NVS is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 01, 2025
Stock price -- (MRK: $89.76 vs. NVS: $111.48)
Brand notoriety: MRK: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: MRK: 85% vs. NVS: 122%
Market capitalization -- MRK: $331.75B vs. NVS: $197.93B
MRK [@Pharmaceuticals: Major] is valued at $331.75B. NVS’s [@Pharmaceuticals: Major] market capitalization is $197.93B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MRK’s FA Score shows that 2 FA rating(s) are green whileNVS’s FA Score has 2 green FA rating(s).

  • MRK’s FA Score: 2 green, 3 red.
  • NVS’s FA Score: 2 green, 3 red.
According to our system of comparison, NVS is a better buy in the long-term than MRK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRK’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 3 bullish TA indicator(s).

  • MRK’s TA Score: 4 bullish, 5 bearish.
  • NVS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, MRK is a better buy in the short-term than NVS.

Price Growth

MRK (@Pharmaceuticals: Major) experienced а -2.76% price change this week, while NVS (@Pharmaceuticals: Major) price change was +0.35% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.53%. For the same industry, the average monthly price growth was -0.90%, and the average quarterly price growth was -6.46%.

Reported Earning Dates

MRK is expected to report earnings on Apr 24, 2025.

NVS is expected to report earnings on Apr 29, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.53% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRK($332B) has a higher market cap than NVS($198B). MRK has higher P/E ratio than NVS: MRK (935.64) vs NVS (23.38). NVS YTD gains are higher at: 18.686 vs. MRK (-8.991). NVS has higher annual earnings (EBITDA): 18.3B vs. MRK (6.91B). NVS has more cash in the bank: 14B vs. MRK (7.09B). NVS has less debt than MRK: NVS (26.3B) vs MRK (35.1B). MRK has higher revenues than NVS: MRK (60.1B) vs NVS (46.7B).
MRKNVSMRK / NVS
Capitalization332B198B168%
EBITDA6.91B18.3B38%
Gain YTD-8.99118.686-48%
P/E Ratio935.6423.384,001%
Revenue60.1B46.7B129%
Total Cash7.09B14B51%
Total Debt35.1B26.3B133%
FUNDAMENTALS RATINGS
MRK vs NVS: Fundamental Ratings
MRK
NVS
OUTLOOK RATING
1..100
7284
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
5715
SMR RATING
1..100
2537
PRICE GROWTH RATING
1..100
6243
P/E GROWTH RATING
1..100
10068
SEASONALITY SCORE
1..100
45n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRK's Valuation (12) in the Pharmaceuticals Major industry is in the same range as NVS (14). This means that MRK’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (15) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (57). This means that NVS’s stock grew somewhat faster than MRK’s over the last 12 months.

MRK's SMR Rating (25) in the Pharmaceuticals Major industry is in the same range as NVS (37). This means that MRK’s stock grew similarly to NVS’s over the last 12 months.

NVS's Price Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as MRK (62). This means that NVS’s stock grew similarly to MRK’s over the last 12 months.

NVS's P/E Growth Rating (68) in the Pharmaceuticals Major industry is in the same range as MRK (100). This means that NVS’s stock grew similarly to MRK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MRKNVS
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
39%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
63%
Bearish Trend 1 day ago
49%
Momentum
ODDS (%)
Bearish Trend 1 day ago
63%
Bearish Trend 1 day ago
48%
MACD
ODDS (%)
Bearish Trend 1 day ago
57%
Bearish Trend 1 day ago
44%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
47%
Bullish Trend 1 day ago
49%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
42%
Bullish Trend 1 day ago
44%
Advances
ODDS (%)
Bullish Trend 1 day ago
48%
Bullish Trend 5 days ago
47%
Declines
ODDS (%)
Bearish Trend 8 days ago
48%
Bearish Trend 7 days ago
43%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
56%
Bearish Trend 1 day ago
52%
Aroon
ODDS (%)
Bullish Trend 1 day ago
50%
Bullish Trend 1 day ago
39%
View a ticker or compare two or three
Ad is loading...
MRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KRG22.370.10
+0.45%
Kite Realty Group Trust
MEC13.43-0.10
-0.74%
Mayville Engineering Company
CMRE9.84-0.12
-1.20%
Costamare
TRP47.21-0.84
-1.75%
TC Energy Corp
KIRK1.26-0.03
-2.33%
Kirkland's

MRK and

Correlation & Price change

A.I.dvisor tells us that MRK and AZN have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MRK and AZN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRK
1D Price
Change %
MRK100%
+0.59%
AZN - MRK
27%
Poorly correlated
-0.39%
JNJ - MRK
24%
Poorly correlated
+1.30%
NVS - MRK
23%
Poorly correlated
-0.97%
PFE - MRK
23%
Poorly correlated
+0.52%
GSK - MRK
22%
Poorly correlated
N/A
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
-0.97%
GSK - NVS
49%
Loosely correlated
N/A
AZN - NVS
48%
Loosely correlated
-0.39%
JNJ - NVS
39%
Loosely correlated
+1.30%
PFE - NVS
38%
Loosely correlated
+0.52%
SNY - NVS
38%
Loosely correlated
-0.64%
More